THE DIFFERENCE OF GASTRIC MUCOSAL INJURY BETWEEN CLOPIDOGREL USER AND PRASUGREL USER IN PATIENT RECEIVING DUAL ANTI-PLATELET THERAPY (DAPT)

Ayato Murata

UEG Week Copenhagen 2023 | Poster

Oesophagus

October 15, 2023

A case-controlled endoscopy study of 82 patients on dual antiplatelet therapy found prasugrel users had significantly less gastric mucosal injury than clopidogrel users, regardless of concomitant acid suppression therapy.

KEY POINTS

- The study compared gastric mucosal injury severity between clopidogrel (group C, n=53) and prasugrel (group P, n=29) users receiving dual antiplatelet therapy with low-dose aspirin, using the modified LANZA score on endoscopy.
- Prasugrel users showed significantly lower average modified LANZA scores than clopidogrel users in both acid-suppression users (0.23±1.07 versus 0.94±1.66, p=0.016) and nonusers (0 versus 1.82±1.88, p=0.031).
- The data were extracted from 6,863 patients who underwent upper gastrointestinal endoscopy between April 2015 and March 2022.
- The authors concluded that prasugrel is more user-friendly than clopidogrel in terms of gastric mucosal injury in dual antiplatelet therapy.
- This material is relevant for gastroenterologists and cardiologists managing patients on dual antiplatelet therapy with concerns about gastrointestinal complications.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/93836386-743b-11ee-936d-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.